Early efficacy of individual regimens containing bedaquiline in patients with drug resistant tuberculosis

Abstract

Objective: To evaluate early efficacy of sputum conversion within 6 months of individual regimens containing bedaquiline in patients with drug resistant tuberculosis. Methods: We conducted a retrospective study among patients with drug resistant tuberculosis who were receiving individual regimens containing bedaquiline. The primary outcome was sputum conversion of both smear and culture within 6 months of treatment. We used medical records of drug resistant tuberculosis patients from January 2020 to December 2021. The study was conducted at Dr. Soetomo Hospital, Indonesia from August to October 2022. Results: In this study, 44 eligible drug resistant tuberculosis patients were initiated on regimens containing bedaquiline. There were 52.3% males and the median age was 45.5 years. The rates of previous treatment (70.5%) and lung cavity (36.4%) were high. The most common companion drugs included clofazimine, cycloserine, levofloxacin, and linezolid. Sputum smear and culture conversion was seen in 79.4% and 82.1% at the 2nd month, respectively. More than 97% patients had smear and culture conversion at the end of 6 months. Conclusions: Among drug resistant tuberculosis patients, individual regimens containing bedaquiline were associated with high rates of smear and culture conversion at the end of 6 months. Early efficacy of regimens containing bedaquiline can be used to predict cure rate at the end of treatment.

Keywords

Bedaquiline / Individual regimen / Drug resistant tuberculosis / Efficacy

References

[1] Johnson JM, Mohapatra AK, Velladath SU, Shettigar KS. Predictors of treatment outcomes in drug resistant tuberculosis-observational retrospective study. Int J Mycobacteriol 2022; 11:38-46.

[2] Viney K, Linh NN, Gegia M. New definitions of pre-extensively and extensively drug-resistant tuberculosis: Update from the World Health Organization. Eur Respir J 2021; 57:2100361.

[3] Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. PLoS One 2021; 16(2):e0246284.

[4] Indarti HT, Kristin E, Soedarsono S, Endarti D. Treatment outcomes of multidrug-resistant tuberculosis patients in East Java, Indonesia: A retrospective cohort analysis. Int J Mycobacteriol 2022; 11:261-267.

[5] World Health Organization. Consolidated guidelines on tuberculosis treatment. Module 4: Treatment-drug resistant tuberculosis treatment. Geneva: World Health Organization ; 2020.

[6] Soedarsono S, Kusmiati T, Wulaningrum PA, Permatasari A, Indrawanto DW. Factors cause of switching shorter regimen to longer regimen in multidrug-resistant/rifampicin-resistant tuberculosis treated patients in Dr. Soetomo Hospital Surabaya, Indonesia. Indian J Forensic Med Toxicol 2021; 15(1):1576-1581.

[7] World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization ; 2020.

[8] Ministry of Health. The Republic of Indonesia joint external monitoring mission for tuberculosis. 2020. [Online]. Available from:https://tbindonesia.or.id/wp-content/uploads/2021/06/INDONESIA-JEMM-2020-Eng-1.pdf. [Accessed on 12 October 2022].

[9] Brust JCM, Gandhi NR, Wasserman S, Maartens G, Omar SV, Ismail NA, et al. Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: A prospective cohort study. Clin Infect Dis 2021; 73(11):2083-2092.

[10] Franke MF, Khan P, Hewison C, Khan U, Huerga H, Seung KJ, et al. Culture conversion in patients treated with bedaquiline and/or delamanid. Am J Respir Crit Care Med 2021; 203(1):111-119.

[11] Li J, Yang G, Cai Q, Wang Y, Xu Y, Zhang R, et al. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. Int J Infect Dis 2021; 110:179-186.

[12] Fekadu G, Yao J, You JHS. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis. PLoS One 2022; 17(8):0272770.

[13] Giraud-Gatineau A, Coya JM, Maure A, Biton A, Thomson M, Bernard EM, et al. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection. Elife 2020; 9:55692.

[14] Fauziah H, Aprianti S, Handayani I, Kadir NA. Analysis of smear microscopy and culture conversion results in multidrug-resistant tuberculosis patients with and without type 2 diabetes mellitus. Indones J Clin Pathol Med Lab 2020; 26(3):272-276.

[15] Megerso A, Deyessa N, Jarso G, Worku A. A retrospective comparative study on median time to sputum culture conversion in multi-drug resistant pulmonary tuberculosis patients in pastoral and non-pastoral settings in southeast oromia, Ethiopia. Infect Drug Resist 2021; 14:5325-5333.

[16] Kenaope L, Ferreira H, Seedat F, Otwombe K, Martinson NA, Variava E. Sputum culture and drug sensitivity testing outcome among X-pert Mycobacterium tuberculosis/rifampicin-positive, rifampicin-resistant sputum: A retrospective study-not all rifampicin resistance is multi-drug resistant. J Glob Antimicrob Resist 2020; 21:434-438.

[17] Li Q, Lu M, Hsieh E, Wu L, Wu Y, Wang M, et al. Time to sputum culture conversion and its predictors among patients with multidrug-resistant tuberculosis in Hangzhou, China: A retrospective cohort study. Medicine 2020; 99(50):e23649.

[18] Javaid A, Ahmad N, Afridi AK, Basit A, Khan AH, Ahmad I, et al. Validity of time to sputum culture conversion to predict cure in patients with multidrug-resistant tuberculosis: A retrospective single-center study. Am J Trop Med Hyg 2018; 98(6):1629-1636.

[19] Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, et al. Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial. PLoS One 2018; 13(7):0200539.

[20] Xi Y, Zhang W, Qiao RJ, Tang J. Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. PLoS One 2022; 17(6):e0270003.

[21] Dutt R, Singh R, Majhi J, Basu G. Status of drug resistant tuberculosis among patients attending a tuberculosis unit of West Bengal: A record based cross-sectional study. J Family Med Prim Care 2022; 11:84-89.

[22] Oladimeji O, Othman Y, Oladimeji KE, Atiba BP, Adepoju VA, Odugbemi BA. Patterns of presentation of drug-resistant tuberculosis in nigeria: A retrospective file review. Microbiol Res 2022; 13:609-619.

[23] Cheng Q, Xie L, Wang L, Lu M, Li Q, Wu Y, et al. Impact of different tuberculosis history at the onset of future multidrug-resistant tuberculosis: A large, retrospective, population-based cohort study. J Glob Antimicrob Resist 2021; 24:158-168.

[24] Mishra G. Nix-TB and ZeNix trials: Paving the way for shorter regimens for drug-resistant tuberculosis. Asian Pac J Trop Med 2021; 14(10):431-432.

[25] Mase S, Chorba T, Parks S, Belanger A, Dwrokin F, Seaworth B, et al. Bedaquiline for the treatment of multidrug-resistant tuberculosis in the United States. Clin Infect Dis 2020; 71(4):1010-1016.

[26] Saktiawati AMI, Subronto YW. Influence of diabetes mellitus on the development of multi drug resistant-tuberculosis in Yogyakarta. Acta Med Indones-Indones J Intern Med 2018; 50(1):11-17.

[27] Liu Q, Li W, Xue M, Chen Y, Du X, Wang C, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: A meta-analysis. Sci Rep 2017; 7:1090.

[28] Song WM, Li YF, Liu JY, Tao NN, Liu Y, Zhang QY, et al. Drug resistance of previously treated tuberculosis patients with diabetes mellitus in Shandong, China. Respir Med 2020; 163:105897.

[29] Wang MC, Cervantes J. Glycemic control in tuberculosis: Lessons learned from Taiwan. Asian Pac J Trop Med 2019; 12(10):438-441.

[30] Song WM, Li YF, Liu JY, Tao NN, Liu Y, Zhang QY, et al. Primary drug resistance among tuberculosis patients with diabetes mellitus: A retrospective study among 7 223 cases in China. Infect Drug Resist 2020; 163:105897.

[31] Shi L, Gao J, Gao M, Deng P, Chen S, He M, et al. Interim effectiveness and safety comparison of bedaquiline-containing regimens for treatment of diabetic versus non-diabetic mdr/xdr-tb patients in China: A multicenter retrospective cohort study. Infect Dis Ther 2021; 10:457-470.

[32] Alffenaar JWC, Akkerman OW, Tiberi S. Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis? Eur Respir J 2020; 55:1901908.

[33] Gour A, Dogra A, Sharma S, Wazir P, Nandi U. Effect of disease state on the pharmacokinetics of bedaquiline in renal-impaired and diabetic rats. ACS Omega 2021; 6:6934-6941.

[34] Sarin R, Vohra V, Singla N, Singla R, Puri MM, Munjal SK, et al. Early efficacy and safety of bedaquiline and delamanid given together in a ‘Salvage Regimen’ for treatment of drug-resistant tuberculosis. Indian J Tuberc 2019; 66:184-188.

[35] Lee HH, Jo KW, Yim JJ, Jeon D, Kang H, Shim TS. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid. Int J Infect Dis 2020; 98:478-485.

[36] Hafkin J, Hittel N, Martin A. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis. Eur Respir J 2019; 53:1801154.

[37] Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidloingmaier F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: A phase 2, open-label, randomised, controlled trial. Lancet Infect Dis 2021; 21:975-983.

[38] Hyun DG, Lee SH, Jo KW, Shim TS. Concurrent, prolonged use of bedaquiline and delamanid for multidrug-resistant tuberculosis. Korean J Med 2019; 94(3):294-298.

[39] Pieterman ED, Keutzer L, van der Meijden A, van den Berg S, Wang H, Zimmerman MD, et al. Superior efficacy of a bedaquiline, delamanid, and linezolid combination regimen in a mouse tuberculosis model. J Infect Dis 2021; 224:1039-1047.

[40] Asadi L, Croxen M, Heffernan C, Dhillon M, Paulsen C, Egedahl ML, et al. How much do smear-negative patients really contribute to tuberculosis transmissions? Re-examining an old question with new tools. eClinicalMedicine 2022; 43:101250.

[41] Kassa GM, Merid MW, Muluneh AG, Fentie DT. Sputum smear grading and associated factors among bacteriologically confirmed pulmonary drug-resistant tuberculosis patients in Ethiopia. BMC Infect Dis 2021; 21:238.

[42] Rasool G, Khan AM, Mohy-Ud-Din R, Riaz M. Detection of Mycobacterium tuberculosis in afb smear-negative sputum specimens through MTB culture and GeneXpert® MTB/RIF assay. Int J Immunopathol Pharmacol 2019; 33:1-6.

[43] Gao M, Gao J, Lie L, Wu G, Chen W, Chen Y, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: A multicentre study. Clin Microbiol Infect 2021; 27:597-602.

[44] Putra ON, Hidayatullah AYN. Treatment outcomes of patients with multidrug-resistant tuberculosis: Concern to bedaquiline. Tuberc Respir Dis 2021; 84:338-339.

[45] Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T, et al. Linezolid-based regimens for multidrug-resistant tuberculosis (TB): A systematic review to establish or revise the current recommended dose for TB treatment. Clin Infec Dis 2018; 67:327-335.

[46] Ammerman NC, Swanson RV, Tapley A, Moodley C, Ngcobo B, Adamson J, et al. Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo. J Antimicrob Chemother 2017; 72:455-461.

[47] Wang MG, Liu XM, Wu SQ, He JQ. Impacts of clofazimine on the treatment outcomes of drug-resistant tuberculosis. Microbes Infect 2023; 25(1-2):105020.

[48] Hu Y, Pertinez H, Liu Y, Davies G, Coates A. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: An in vivo model of a potential cure. J Antmicrob Chemother 2019; 74(6):1627-1633.